Updated look and feel – Drug Selection Screen

Previous Screen

Age: 64 - Female Height: 60in Weight: 150lb BSA: 1	1.70		
Regimen Search			3
* Choose a Cancer Type: * Select an ICD10 Code :	Colon C18.2 Malignant neoplasm of ascendin	▼ ng colon	
* Enter a Drug Name or HCPC Code:	Enter ALL drugs being prescrib your treatment entry. Enter a Drug Name or a HCPC Code or	ed by your physician to start	Drugs Frequently Ordered With Selection irinotecan HCI
Chemotherapy Drugs: • Oxaliplatin (J9263) • Fluorouracil (J9190) • Leucovorin Calcium (J8999, J0 • Bevacizumab (J9035) • The regimen search logic will I	640) be based on the items entered above.	Supportive Drugs: Pegfilgrastim,SC (J2506)	
	The patient is enrolled	enrolling on the MATCH Trial.	
M Previous			Save and Continue

New Screen

Search	
Drugs	Regimen
HCPCS, Generic or Brand Name	
	You may only request one Regimen for each authorization: however, you may add additional Drugs to the selected Regimen. To search for another Regimen, please remove the selected Regimen.
Selected Regimen	
bevacizumab, fluorouracil, leucovorin and oxaliplatin (bev FOLFOX)	× Delete
J9263 Oxaliplatin (Oxaliplatin) IV	
J9190 Fluorouracil (Fluorouracil) IV	
Select Drugs:	
Q5107 Bevacizumab-awwb (Mvasi) IV	•
J0640 Leucovorin Calcium (Leucovorin Calcium) IJ	-
Selected Drugs	
J2506 Pegfilgrastim (Neulasta) SC	× Delete
	L ³
CANCEL	CONTINUE

A user can individually enter drugs to make up a regimen using the Drugs search box. Or a user can search for the Regimen by name or nickname to populate all drugs in that regimen.

The HCPCS Code, generic name, brand name and route of administration will be shown for each drug.

Updated Look and Feel – Cancer Type and Diagnosis Screens

Previous Screen

ter Diagnosis			
* Pathology:	Adenocarcinoma	•	
* Stage:	IV	•	
	I want to enter T, N, M to calculate Stage		
* ICD10:	C18.3 Malignant neoplasm of hepatic flexure	•	
* Bio-Markers & Tumor Characteristics:			
BRAF status:	Wild Type	•	
k-ras genotype:	Not reported	•	
Microsatellite Instability:	Not reported	•	
n-ras genotype:	Not reported	•	
NTRK Fusion:	Not reported	•	
* Line of Treatment:	First Line	v 0	
* Performance Status:	0 - Normal activity (asymptomatic).	•	

New Screen

Users will select the **Tumor type, Pathology, Stage, Line of Treatment** from the dropdown menus.

Selections on this screen will modify any subsequent biomarker or clinical justification questions asked later in the process.

Clinical Scenario	
Tumor Type *	
Colon	•
Pathology * You can find this information in the pathology section of the electronic record	1e
Adenocarcinoma	•
Stage O TNM Values	
Stage *	
Stage IV	٠
Line of Treatment *	
1st Line	•
CANCEL BACK	

Unnecessary biomarker questions removed

Previous Screen

Diagnosis			
* Pathology:	Adenocarcinoma	•	
* Stage:	IV	•	
	I want to enter T, N, M to calculate Stage		
* ICD10:	C18.3 Malignant neoplasm of hepatic flexure	•	
* Bio-Markers & Tumor Characteristics:			
BRAF status:	Wild Type	•	
k-ras genotype:	Not reported	•	
Microsatellite Instability:	Not reported	•	
n-ras genotype:	Not reported	•	
NTRK Fusion:	Not reported	•	
* Line of Treatment:	First Line	• 0	
* Performance Status:	0 - Normal activity (asymptomatic).	•	

New Screen

Biomarkers	
What are the biomarker (or other tests listed below) results?	
BRAF BRAF Mutated BRAF Wild-Type O BRAF Unknown	
KRAS KRAS Mutated KRAS Wild-Type O KRAS Unknown	
NRAS Mutated NRAS Wild-Type O NRAS Unknown	
NTRK 1/2/3 gene fusion NTRK 1/2/3 Positive NTRK 1/2/3 Negative NTRK 1/2/3 Positive NTRK 1/2/3 Unknown	
CANCEL BACK	SAVE & EXIT CONTINUE

Clinical algorithms have been revised to properly identify which biomarkers would be applicable based on the **drug regimen** entered by the user, not the overall **cancer type**.

Users will only need to answer biomarker questions applicable to the drugs requested.

Early identification of available Pathway regimens

Previous Screen

olon	er Type: Che OX. FLL LEL Bev	motherapy Drugs: ALIPLATIN IOROURACIL ICOVORIN CALCIUM acizumab			
Thad	he following regimens contain ALL of the requested therapeutic di dministration for the prescribed treatment. Pathway (📀) regimen	ugs. Please select the regin is are also identified when a	nen that most clos vailable.	ely reflects the setting and	
	Name		Line of Treatment	Stages	
•	FOLFOX-6 - Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Avastin IV/Recurrent, First Line)	(Bevacizumab) (Stages IIIC-	First Line	IIIC , IV , IVA , IVB , IVC , Recurrent	•
•	FOLFOX-6 - Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Avastin IV/Recurrent, Second Line or Greater)	(Bevacizumab) (Stages IIIC-	Second Line or Greater	IIIC , IV , IVA , IVB , IVC , Recurrent	•
•	FOLFOX-7 - Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Avastin IV/Recurrent, First Line or Greater)	(Bevacizumab) (Stages IIIC-	First Line or Greater	IIIC , IV , IVA , IVB , IVC , Recurrent	

New Screen

Based on the patient's diagnosis and the biomarker test results, the Alternative Regimens screen appears showing any eligible On-Pathway alternative regimens.

Alternative Regimens		
Selected Drugs		
You have requested drugs that may require additional rev Q5107 Bevacizumab-awwb (Mvasi) IV J9190 Fluorouracii (Fluorouracii) IV J0640 Leucovorin Calcium (Leucovorin Calcium) IJ J9263 Oxaliplatin (Oxaliplatin) IV	view:	
Alternative Regimens Based on your clinical scenario, please consider choosing	an alternative Regimen by selecting a row in the table below and clickin	다. g 'Update Regimen' to continue.
Regimen Name (Nickname)	Required Biomarker(s)	Pathway Eligible
Keytruda (Keytruda)	BRAF, KRAS, MSI/MMR, NRAS, NTRK 1/2/3	Yes
CANCEL BACK	SAVE & EXIT	CONTINUE WITH CURRENT DRUG SELECTION

Revised dosing schedule for ease of input

Previous Screen

Please verify or edit item inform Press 🖋 Save and Continue if r	ation by clicking on each drug below. 10 changes are needed.					© Sa	ave Draft
Enter Chemotherapy Deta	ils						
Drug Name	D)ose	Cycle Range	Cycle Length	Days of Administration	Frequence Per Day	çy
Please review the drugs detail	s below and click a row to modify						
Bevacizumab, IV (J9035)	27	72.16mg To I	Progression	14	1	QD	->
Fluorouracil, IVP (J9190)		608mg To F	Progression	14	1	QD	>
Fluorouracil, CIV (J9190)		3648mg To F	Progression	14	1	QD	>
Oxaliplatin, IV (J9263)		129.2mg To F	Progression	14	1	QD	>
Leucovorin Calcium, IV (J06/ Leucovorin Calcium, OR (J8)	Cancel Edit Drug: Bevacizumab						Accept Cha
Please select from the following of the	Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen.	er drug schedul	les (i.e. Cycles/	Cycle Range,	Cycle Length, Days of	Administration	Accept Cha
View Control of the	✔ Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen.	er drug schedul Drug	les (i.e. Cycles/ Bevacizun	Cycle Range, nab	. Cycle Length, Days of	Administration	Accept Cha
Prease select from the following ✓ Leucovorin Calcium, IV (J064 Leucovorin Calcium, OR (J8)	4 Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen.	er drug schedul Drug Route	les (i.e. Cycles/ Bevacizun Intravenous	Cycle Range, nab	Cycle Length, Days of	Administration	* Accept Cha
Please select from the following of the	✔ Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen.	er drug schedul Drug Route Dose	les (i.e. Cycles/ Bevacizun Intravenous 272.16	Cycle Range; nab	Cycle Length, Days of	Administration	 Accept Chat Frequency
View Control Calcium, IV (J84 Leucovorin Calcium, OR (J84	✔ Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen.	er drug schedul Drug Route Dose Sub Route	les (I.e. Cycles/ Bevacizun Intravenous 272.16 Intravenous	Cycle Range, nab	Cycle Length, Days of	Administration mg mg	Accept Cha Frequency
Piese select from the follow: ✓ Leucovorin Calcium, IV (J064 Leucovorin Calcium, OR (J8)	✔ Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen. Is Drug Off-Cycle or Outsi	er drug schedul Drug Route Dose Sub Route ide of Cycle?	les (i.e. Cycles/ Bevacizun Intravenous 272.16 Intravenous	Cycle Range, nab	Cycle Length, Days of	Administration	 Accept Chat Frequency
Prese select from the follow: ✓ Leucovorin Calcium, IV (J064 Leucovorin Calcium, OR (J8)	✔ Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen. Is Drug Off-Cycle or Outsi Cyclessi NOTE: Enter Cycles at 1 as 1 as 1.2	er drug schedul Drug Route Dose Sub Route ide of Cycle? ICycle Range 3 <u>OF</u> simply 3	les (i.e. Cycles/ Bevacizun Intravenous 272.16 Intravenous I.2,3,4,5,6,7/	Cycle Range. nab	Cycle Length, Days of	Administration mg mg	Accept Cha , Frequency
Prease select from the following of the	✔ Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen. Is Drug Off-Cycle or Outsi NOTE: Enter Cycles as 1-3 or 12.3 Drug will be administered until the patient's disease	er drug schedul Drug Route Dose Sub Route ide of Cycle? (Cycle Range 3 <u>NOT</u> simply 3. progresses?	les (i.e. Cycles/ Bevacizun Intravenous 272.16 Intravenous 1,2,3,4,5,6,7/ 2	Cycle Range. nab	Cycle Length, Days of	Administration	Accept Cha
Vieucovorin Calcium, IV (J064 Leucovorin Calcium, OR (J8)	✔ Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen. Is Drug Off-Cycle or Outsis Cycless NOTE: Enter Cycles at 1-3 or 1,2; Drug will be administered until the patient's disease	er drug schedul Drug Route Dose Sub Route ide of Cycle? iCycle Range 3 <u>b07</u> simily 3. progresses? Cycle Length	les (i.e. Cycles/ Bevacizun Intravenous 272.16 Intravenous 1,2,3,4,5,6,7/ 2 14	Cycle Range. nab	Cycle Length, Days of	Administration	Accept Cha
Vieucovorin Calcium, IV (J064 Leucovorin Calcium, OR (J8)	✔ Cancel Edit Drug: Bevacizumab When reviewing regimens, the program may conside Per Day) in selection of an On-Pathway regimen. Is Drug Off-Cycle or Outsi NoTE: Enter Cycles as 15 or 12. Drug will be administered until the patient's disease O Days of Action	er drug schedul Drug Route Dose Sub Route ide of Cycle? (Cycle Range 3 <u>NOT</u> simply 3. progresses? Cycle Langth dministration	les (i.e. Cycles/ Bevacizun Infravenous 272.16 Infravenous 1,2,3,4,5,6,7) 14	Cycle Range nab	Cycle Length, Days of	Administration	 Accept Chains Frequency

New Screen

Dosing schedule screen displays all drug dosing details for easy review and quick edits.

Once the height and weight is entered, the total dose or Final Dose for each drug is calculated.

eight*	Unit*	Weight*	Unit*		CREATE	NEW DOSING SCHEDUL
50	inches 🔹	120	pounds	•		
		Ş				
Bev- FOLFOX6 - Pathway	Ineligible					🥒 Edi
Drugs	Dose Amount	Final Dose	Route	Schedule	Cycle Length	Cycles
Bevacizumab (Avastin) Oxaliplatin (Oxaliplatin) Fluorouracii (Fluorouraci Fluorouracii (Fluorouraci Leucovorin Calcium (Leu Calcium)	5.000 MG/KG 85.000 MG/M2 400.000 MG/M 1,200.000 MG/ 400.000 MG/M	272.000 MG 129.200 MG 2 608.000 MG M2 1,824.000 MG 2 608.000 MG	{"IV"} {"IV"} {"IV"} {"IV"}	D1 D1 D1, 2 D1	14 Days	Cycle 1
Leucovorin Calcium (Leu Calcium)	400.000 MG/M	2 608.000 MG	{"IV"}	D1		SELE